Hepatitis C
Material: | Antibody demonstration: 1 ml serum (Immunoblot) PCR: 2 ml EDTA-blood 2 ml serum |
Methods: |
Ligandenassays → Chemilumineszenz-Immunoassay (CLIA) Amplifikationsverfahren → Real-time-PCR Ligandenassays → Immunoblot | Criteria for evaluation | Anti-HCV-IgG/IgM: negative |
Indication | Suspicion of hepatitis, especially in high-risk patients (homosexuals, drug-addicts) or after transfusions | Mandatory reporting | ja Serological demonstration of hepatitis C antibodies (confirmed by immunoblot) or direct virus demonstration by PCR has to be reported to the responsible health department by the laboratory, stating the patient’s name. |
Please note | Antibody demonstration in the immunoassay requires verification by immunoblot. Infectiosity and activity of the disease has to be determined by quantitative HCV-RNA evaluation. HCV-RNA demonstration indicates active infection. HCV-RNA starts to show in the first 2 weeks of the incubation period. Quantitative evaluation in case of chronic HCV-infection serves the purpose of determining viral load. This correlates with the severity of the course of a liver disease. Possible therapy indication and planning includes not only a number of clinical aspects but also the viral load and the HCV-genotype (see there).
Clinical course of HCV-infection: In 15 % of cases, there is spontaneous healing. In 25 % of cases, infection is asymptomatic with normal GOT- and GPT values and generally benign histological liver changes. In 60 % of cases, there are mild symptoms with moderate lesions and minimal fibrosis. Approximately 20 % of these patients develop liver cirrhosis within 10 – 20 years, with the following factors influencing the speed of progression:
|
Accredited | ja |
More Results for the letter H
- H2 breath test (H2ATEM)
- Lactose-H2 breath test, fructose-H2 breath test, sorbit-H2 breath test, glucose-H2 breath test
- Hair analysis for drugs (HAIR01)
- opiates, methadon, cannabis, amphetamines, methamphetamines, cocaine
- Hair analysis for metals (HAARE2)
- Arsenic, lead, cadmium, copper, mercury, palladium, zinc and others
- Haloperidol (HAL)
- HAMA (HAMA)
- human anti-mouse antibodies
- Hanta viruses (HANTAV)
- Serotypes Hantaan, Seoul, Puumala
- Haptoglobin (HP)
- HBDH (HBDH)
- Alpha-hydroxybutyric dehydrogenase, LDH1
- HBV resistance/subtype (HBVTDF)
- HCG in serum (β-) (HCG(b))
- human chorionic gonadotropin
- HCG in urine (β-) (HCG(b))
- human chorionic gonadotropin
- HDL cholesterol (HDL)
- HE 4 (HE 4)
- Human epididymis protein
- Helicobacter pylori (KHELI, PHELI)
- Helicobacter pylori 13C breath test (ATEMB)
- HELLP syndrome (HELLP)
- Hemochromatosis gene mutation (HLAH)
- HFE gene mutation
- Hemoglobin A1c (HBAAC)
- HbA1c
- Hemoglobin F cells (HBFZ)
- Fetal erythrocytes, fetomaternal transfusion
- Hemoglobin, free (FRHB)
- Hemoglobin-electrophoresis (HBL)
- Hemoglobinopathy, molecular genetic evaluation (HMO)
- Hemolysins (KAEH)
- Hemophilus ducreyi (HAEDUC)
- Soft chancre
- Hemophilus influenzae (KHAEM, HAEINF)
- Hemorrhagic fever, viral (VHF)
- Heparin platelet factor 4 complex antibodies (HIPAHE)
- HIT-diagnostics
- Heparin, low molecular weight (AFXAL)
- LMW heparin
- Hepatitis A (HAV)
- Hepatitis B (AHBC)
- Anti-HBc-IgG